

Richard G Frank

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7923938/publications.pdf>

Version: 2024-02-01

113
papers

6,866
citations

87888

38
h-index

62596

80
g-index

119
all docs

119
docs citations

119
times ranked

5563
citing authors

#	ARTICLE	IF	CITATIONS
1	Toward Greater Accountability in Mental Health Care. <i>Psychiatric Services</i> , 2023, 74, 182-187.	2.0	1
2	Biosimilar competition: Early learning. <i>Health Economics (United Kingdom)</i> , 2022, 31, 647-663.	1.7	9
3	Assessing the long-term effects of Basic Medical Insurance on catastrophic health spending in China. <i>Health Policy and Planning</i> , 2022, 37, 747-759.	2.7	6
4	What policies the US Food and Drug Administration should pursue in response to the addiction and overdose crisis. <i>Addiction</i> , 2022, 117, 1198-1199.	3.3	1
5	The Price to Consumers of Generic Pharmaceuticals: Beyond the Headlines. <i>Medical Care Research and Review</i> , 2021, 78, 585-590.	2.1	4
6	Addressing the Risk of Medicare Trust Fund Insolvency. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 341.	7.4	8
7	Transforming Mental Health And Addiction Services. <i>Health Affairs</i> , 2021, 40, 226-234.	5.2	47
8	Jobs for People With Mental Health Conditions: Trends and Prospects. <i>Psychiatric Services</i> , 2021, 72, 143-147.	2.0	0
9	Our Other Epidemic: Addiction. <i>JAMA Health Forum</i> , 2021, 2, e210273.	2.2	0
10	Decline In New Starts Of Psychotropic Medications During The COVID-19 Pandemic. <i>Health Affairs</i> , 2021, 40, 904-909.	5.2	11
11	Banbury Forum Consensus Statement on the Path Forward for Digital Mental Health Treatment. <i>Psychiatric Services</i> , 2021, 72, 677-683.	2.0	65
12	The Evolution of Supply and Demand in Markets for Generic Drugs. <i>Milbank Quarterly</i> , 2021, 99, 828-852.	4.4	9
13	Behavioral health carveouts : Do they impede access or prioritize the neediest?. <i>Health Services Research</i> , 2021, 56, 802-804.	2.0	1
14	COMMENTARY: Medicaid Expansion and Mental Health Care and Coverage. <i>Journal of Mental Health Policy and Economics</i> , 2021, 24, 97-99.	0.6	0
15	Uninsured by Choice? A choice experiment on long term care insurance. <i>Journal of Economic Behavior and Organization</i> , 2020, 173, 422-434.	2.0	12
16	Behavioral Health Parity Efforts in the US. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 447.	7.4	8
17	Therapies Offered at Residential Addiction Treatment Programs in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 804.	7.4	41
18	Overtuning the ACA's Medicaid Expansion Would Likely Decrease Low-Income, Reproductive-Age Women's Healthcare Spending and Utilization. <i>Inquiry (United States)</i> , 2020, 57, 004695802098146.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Medicaid Expansion's Spillover to the Criminal Justice System: Evidence from Six Urban Counties. <i>Rsf</i> , 2020, 6, 244.	1.2	13
20	The impact of expanded Medicaid eligibility on access to naloxone. <i>Addiction</i> , 2019, 114, 1567-1574.	3.3	18
21	Improving the Child Welfare System to Respond to the Needs of Substance-Exposed Infants. <i>Hospital Pediatrics</i> , 2019, 9, 651-654.	1.3	19
22	Generic Drug Policy and Suboxone to Treat Opioid Use Disorder. <i>Journal of Law, Medicine and Ethics</i> , 2019, 47, 43-53.	0.9	7
23	Changing Medicare's Protected Classes: History, Mistrust, and Budgets in the Prescription Drug Market. <i>Psychiatric Services</i> , 2019, 70, 858-859.	2.0	1
24	In Rural Areas, Buprenorphine Waiver Adoption Since 2017 Driven By Nurse Practitioners And Physician Assistants. <i>Health Affairs</i> , 2019, 38, 2048-2056.	5.2	78
25	The Trump Administration's Actions to Address the Opioids Public Health Crisis"Reply. <i>JAMA Psychiatry</i> , 2019, 76, 101.	11.0	1
26	Making Choice and Competition Work in Individual Insurance in Health Reform Proposals. Issue Brief (Commonwealth Fund), 2019, 2019, 1-11.	0.9	1
27	Market Concentration and Potential Competition in Medicare Advantage. Issue Brief (Commonwealth) Tj ETQq1 1 0.784314 2gBT /Ow	0.9	1
28	Friction in the Path to Use of Biosimilar Drugs. <i>New England Journal of Medicine</i> , 2018, 378, 791-793.	27.0	16
29	Work Requirements in Medicaid for People With Mental Illnesses and Substance Use Disorders. <i>Psychiatric Services</i> , 2018, 69, 626-627.	2.0	6
30	Making the Opioid Public Health Emergency Effective. <i>JAMA Psychiatry</i> , 2018, 75, 767.	11.0	38
31	Reflections on the Mental Health Parity and Addiction Equity Act After 10 Years. <i>Milbank Quarterly</i> , 2018, 96, 615-618.	4.4	5
32	Friction in the Path to Use of Biosimilar Drugs. <i>New England Journal of Medicine</i> , 2018, 378, 2147-2148.	27.0	3
33	Addressing the Fentanyl Threat to Public Health. <i>New England Journal of Medicine</i> , 2017, 376, 605-607.	27.0	194
34	Realizing the Promise of Parity Legislation for Mental Health. <i>JAMA Psychiatry</i> , 2017, 74, 117.	11.0	12
35	Care for the Vulnerable vs. Cash for the Powerful " Trump's Pick for HHS. <i>New England Journal of Medicine</i> , 2017, 376, 103-105.	27.0	12
36	Regulated Medicare Advantage And Marketplace Individual Health Insurance Markets Rely On Insurer Competition. <i>Health Affairs</i> , 2017, 36, 1578-1584.	5.2	9

#	ARTICLE	IF	CITATIONS
37	MEASURING ADVERSE SELECTION IN MANAGED HEALTH CARE. , 2017, , 29-57.		8
38	The Impact of Nursing Home Payâ€forâ€Performance on Quality and Medicare Spending: Results from the Nursing Home Valueâ€Based Purchasing Demonstration. Health Services Research, 2017, 52, 1387-1408.	2.0	33
39	Passive Enrollment Of Dual-Eligible Beneficiaries Into Medicare And Medicaid Managed Care Has Not Met Expectations. Health Affairs, 2017, 36, 846-854.	5.2	21
40	Demand-Side Factors Associated with the Purchase of Long-Term Care Insurance. Forum for Health Economics and Policy, 2016, 19, 23-43.	0.8	4
41	Economics and the Transformation of the Mental Health System. Journal of Health Politics, Policy and Law, 2016, 41, 541-558.	1.9	2
42	Dominated choices and Medicare Advantage enrollment. Journal of Economic Behavior and Organization, 2015, 119, 72-83.	2.0	19
43	What is the impact of policy differences on nursing home utilization? The cases of Germany and the Netherlands. Health Policy, 2015, 119, 814-820.	3.0	24
44	Together4Health: Integrating Care for Vulnerable Populations. American Journal of Psychiatric Rehabilitation, 2015, 18, 105-127.	0.7	1
45	Paying for Early Interventions in Psychoses: A Three-Part Model. Psychiatric Services, 2015, 66, 677-679.	2.0	14
46	The Nature of Pharmaceutical Competition: Implications for Antitrust Analysis. International Journal of the Economics of Business, 2015, 22, 301-343.	1.7	3
47	Behavioral Health Parity and the Affordable Care Act. Journal of Social Work in Disability and Rehabilitation, 2014, 13, 31-43.	0.6	109
48	Factors Associated With High Levels Of Spending For Younger Dually Eligible Beneficiaries With Mental Disorders. Health Affairs, 2014, 33, 1006-1013.	5.2	12
49	Enrollment in Medicare Advantage Plans in Miami-Dade County. Inquiry (United States), 2013, 50, 202-215.	0.9	16
50	Using Shared Savings to Foster Coordinated Care for Dual Eligibles. New England Journal of Medicine, 2013, 368, 404-405.	27.0	8
51	Medication Use and Spending Trends Among Children With ADHD in Florida's Medicaid Program, 1996â€2005. Psychiatric Services, 2012, 63, 115-121.	2.0	19
52	Longâ€Term Care Financing in the United States: Sources and Institutions. Applied Economic Perspectives and Policy, 2012, 34, 333-345.	5.6	44
53	Customization in prescribing for bipolar disorder. Health Economics (United Kingdom), 2012, 21, 653-668.	1.7	8
54	The Evolving Private Psychiatric Inpatient Market. Journal of Behavioral Health Services and Research, 2011, 38, 122-131.	1.4	8

#	ARTICLE	IF	CITATIONS
55	Medicare Drug Prices and the Deficit. <i>New England Journal of Medicine</i> , 2011, 365, 1657-1659.	27.0	2
56	The Rise and Fall of Gabapentin for Bipolar Disorder. <i>Medical Care</i> , 2010, 48, 372-379.	2.4	28
57	Can you get what you pay for? Pay-for-performance and the quality of healthcare providers. <i>RAND Journal of Economics</i> , 2010, 41, 64-91.	2.3	149
58	Behavioral Health Services for Women Who Have Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 706-712.	1.6	28
59	Trends In Mental Health Cost Growth: An Expanded Role For Management?. <i>Health Affairs</i> , 2009, 28, 649-659.	5.2	49
60	Health Insurance Exchanges â€” Making the Markets Work. <i>New England Journal of Medicine</i> , 2009, 361, 1135-1137.	27.0	16
61	DEMAND RESPONSE TO COST SHARING UNDER MANAGED HEALTH CARE. <i>Contemporary Economic Policy</i> , 2009, 27, 1-15.	1.7	5
62	Choice, price competition and complexity in markets for health insurance. <i>Journal of Economic Behavior and Organization</i> , 2009, 71, 550-562.	2.0	117
63	ECONOMIC INCENTIVES AND CONTRACTS: THE USE OF PSYCHOTROPIC MEDICATIONS. <i>Contemporary Economic Policy</i> , 2008, 26, 49-72.	1.7	11
64	Should Drug Prices Be Negotiated Under Part D Of Medicare? And If So, How?. <i>Health Affairs</i> , 2008, 27, 33-43.	5.2	64
65	Special Section on Implications of CATIE: Policy Toward Second-Generation Antipsychotic Drugs: A Cautionary Note. <i>Psychiatric Services</i> , 2008, 59, 521-522.	2.0	6
66	Depression in primary care: quality improvement and economics. <i>Managed Care</i> , 2008, 17, 22-4; discussion 25-6.	0.3	0
67	Managed Behavioral Health Care Carve-Outs: Past Performance and Future Prospects. <i>Annual Review of Public Health</i> , 2007, 28, 303-320.	17.4	59
68	Mental Health In The Mainstream Of Health Care. <i>Health Affairs</i> , 2007, 26, 1539-1541.	5.2	7
69	Was Part D a Giveaway to the Pharmaceutical Industry?. <i>Inquiry (United States)</i> , 2007, 44, 15-25.	0.9	4
70	An Analysis of Price Discrimination in Brand Name Drug Wholesaling. <i>International Journal of the Economics of Business</i> , 2007, 14, 299-315.	1.7	0
71	Custom-made versus ready-to-wear treatments: Behavioral propensities in physiciansâ€™ choices. <i>Journal of Health Economics</i> , 2007, 26, 1101-1127.	2.7	86
72	The Ongoing Regulation of Generic Drugs. <i>New England Journal of Medicine</i> , 2007, 357, 1993-1996.	27.0	112

#	ARTICLE	IF	CITATIONS
73	Regulation of Follow-on Biologics. <i>New England Journal of Medicine</i> , 2007, 357, 841-843.	27.0	36
74	Impact of a Media Campaign for Disaster Mental Health Counseling in Post-September 11 New York. <i>Psychiatric Services</i> , 2006, 57, 1304-1308.	2.0	23
75	Impact of Alternative Interventions on Changes in Generic Dispensing Rates. <i>Health Services Research</i> , 2006, 41, 1876-1894.	2.0	45
76	Behavioral Health Insurance Parity for Federal Employees. <i>New England Journal of Medicine</i> , 2006, 354, 1378-1386.	27.0	199
77	The Costs Of Mental Health Parity: Still An Impediment?. <i>Health Affairs</i> , 2006, 25, 623-634.	5.2	48
78	Changes In Mental Health Financing Since 1971: Implications For Policymakers And Patients. <i>Health Affairs</i> , 2006, 25, 601-613.	5.2	37
79	What Is the Empirical Basis for Paying for Quality in Health Care?. <i>Medical Care Research and Review</i> , 2006, 63, 135-157.	2.1	271
80	Mental Health Policy and Psychotropic Drugs. <i>Milbank Quarterly</i> , 2005, 83, 271-298.	4.4	65
81	Prevalence and Treatment of Mental Disorders, 1990 to 2003. <i>New England Journal of Medicine</i> , 2005, 352, 2515-2523.	27.0	1,592
82	Talbott and Financing Policy: Reducing Fragmentation. <i>Psychiatric Services</i> , 2004, 55, 1150-1151.	2.0	0
83	Prescription-Drug Prices. <i>New England Journal of Medicine</i> , 2004, 351, 1375-1377.	27.0	15
84	Quality-constant "prices" for the ongoing treatment of schizophrenia: an exploratory study. <i>Quarterly Review of Economics and Finance</i> , 2004, 44, 390-409.	2.7	17
85	Effects of Pharmaceutical Promotion on Adherence to the Treatment Guidelines for Depression. <i>Medical Care</i> , 2004, 42, 1176-1185.	2.4	143
86	The Effect of a Managed Behavioral Health Carve-Out on Quality of Care for Medicaid Patients Diagnosed as Having Schizophrenia. <i>Archives of General Psychiatry</i> , 2004, 61, 442.	12.3	62
87	Evaluating selection out of health plans for medicaid beneficiaries with substance abuse. <i>Journal of Behavioral Health Services and Research</i> , 2003, 30, 78-92.	1.4	4
88	Medicaid And Mental Health: Be Careful What You Ask For. <i>Health Affairs</i> , 2003, 22, 101-113.	5.2	145
89	Government Commitment And Regulation Of Prescription Drugs. <i>Health Affairs</i> , 2003, 22, 46-48.	5.2	11
90	Design Of Mental Health Benefits: Still Unequal After All These Years. <i>Health Affairs</i> , 2003, 22, 127-137.	5.2	58

#	ARTICLE	IF	CITATIONS
91	Evaluating Selection Out of Health Plans for Medicaid Beneficiaries with Substance Abuse. Journal of Behavioral Health Services and Research, 2003, 30, 78-92.	1.4	1
92	Aligning Incentives in the Treatment of Depression in Primary Care With Evidence-Based Practice. Psychiatric Services, 2003, 54, 682-687.	2.0	111
93	Promotion of Prescription Drugs to Consumers. New England Journal of Medicine, 2002, 346, 498-505.	27.0	384
94	Using Elicitation Techniques to Estimate the Value of Ambulatory Treatments for Major Depression. Medical Decision Making, 2002, 22, 245-261.	2.4	13
95	The medical treatment of depression, 1991-1996: productive inefficiency, expected outcome variations, and price indexes. Journal of Health Economics, 2002, 21, 373-396.	2.7	84
96	Prescription Drug Prices: Why Do Some Pay More Than Others Do?. Health Affairs, 2001, 20, 115-128.	5.2	94
97	Will Parity in Coverage Result in Better Mental Health Care?. New England Journal of Medicine, 2001, 345, 1701-1704.	27.0	51
98	The Creation of Medicare and Medicaid: The Emergence of Insurance and Markets for Mental Health Services. Psychiatric Services, 2000, 51, 465-468.	2.0	15
99	Risk adjustment of capitation payments to behavioral health care carve-outs: how well do existing methodologies account for psychiatric disability?. Health Care Management Science, 2000, 3, 159-169.	2.6	15
100	Measuring adverse selection in managed health care. Journal of Health Economics, 2000, 19, 829-854.	2.7	162
101	The Value Of Mental Health Care At The System Level: The Case Of Treating Depression. Health Affairs, 1999, 18, 71-88.	5.2	75
102	Medical Resource Use and Cost of Venlafaxine or Tricyclic Antidepressant Therapy. Pharmacoeconomics, 1999, 15, 495-505.	3.3	11
103	Parity for mental health and substance abuse care under managed care. , 1998, 1, 153-159.		17
104	Cost-effectiveness of Treatments for Major Depression in Primary Care Practice. Archives of General Psychiatry, 1998, 55, 645.	12.3	269
105	The Politics And Economics Of Mental Health "Parity" Laws. Health Affairs, 1997, 16, 108-119.	5.2	65
106	The impact of psychiatric disorders on work loss days. Psychological Medicine, 1997, 27, 861-873.	4.5	571
107	Some Economics of Mental Health 'Carve-Outs'. Archives of General Psychiatry, 1996, 53, 933.	12.3	89
108	Risk Contracts in Managed Mental Health Care. Health Affairs, 1995, 14, 50-64.	5.2	117

#	ARTICLE	IF	CITATIONS
109	A Model Mental Health Benefit in Private Health Insurance. Health Affairs, 1992, 11, 98-117.	5.2	42
110	Financing Care of the Severely Mentally Ill: Incentives, Contracts, and Public Responsibility. Journal of Social Issues, 1989, 45, 131-144.	3.3	13
111	PRICING AND LOCATION OF PHYSICIAN SERVICES IN MENTAL HEALTH*. Economic Inquiry, 1985, 23, 115-133.	1.8	21
112	Price Indexes for Medical Care Goods and Services. , 0, , 141-198.		12
113	Treatment Price Indexes for Acute Phase Major Depression. , 0, , 463-505.		8